News
EC approves new Sarclisa indication
The European Commission has approved Sanofi’s Sarclisa in combination with standard of care regimen carfilzomib and dexamethasone (Kd) for the treatment of relapsed multiple myeloma.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The European Commission has approved Sanofi’s Sarclisa in combination with standard of care regimen carfilzomib and dexamethasone (Kd) for the treatment of relapsed multiple myeloma.